PE20140771A1 - Anticuerpos anti-ige apoptoticos - Google Patents

Anticuerpos anti-ige apoptoticos

Info

Publication number
PE20140771A1
PE20140771A1 PE2013000851A PE2013000851A PE20140771A1 PE 20140771 A1 PE20140771 A1 PE 20140771A1 PE 2013000851 A PE2013000851 A PE 2013000851A PE 2013000851 A PE2013000851 A PE 2013000851A PE 20140771 A1 PE20140771 A1 PE 20140771A1
Authority
PE
Peru
Prior art keywords
hvr
seq
includes residues
ige antibodies
nos
Prior art date
Application number
PE2013000851A
Other languages
English (en)
Inventor
Lawren Wu
Mercedesz Balazs
Hans Brightbill
Andrew Chan
Yvonne Chen
Anan Chuntharapai
Mark Dennis
Terence Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39709011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140771(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20140771A1 publication Critical patent/PE20140771A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

SE REFIERE HA ANTICUERPOS ANTI-IGE, DONDE: EL HVR-L1 COMPRENDE RESIDUOS 24-34 DE LA SEQ ID NOS: 21, 22, 23 ENTRE OTROS;EL HVR-L2 COMPRENDE RESIDUOS 50-56 DE SEQ ID NOS: 21,22,23, ENTRE OTROS; EL HVR-L3 COMPRENDE RESIDUOS 89-97 DE SEQ ID NOS: 24,25,26, ENTRE OTROS; EL HVR-H1 COMPRENDE RESIDUOS 26-35 DE SEQ ID NOS: 33,34,35, ENTRE OTROS; EL HVR-H2 COMPRENDE RESIDUOS 49-65 DE SEQ ID NO: 36,,37,38 ENTRE OTRSO; EL HVR-H3 COMPRENDE RESIDUOS 93-102 DE SEQ ID NO: 33,34, ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA QUE SON UTILES EN EL TRATAMIENTO DE TRASTORNOS MEDIADO POR IgE.
PE2013000851A 2007-03-22 2008-03-24 Anticuerpos anti-ige apoptoticos PE20140771A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89633907P 2007-03-22 2007-03-22

Publications (1)

Publication Number Publication Date
PE20140771A1 true PE20140771A1 (es) 2014-07-07

Family

ID=39709011

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008000526A PE20090726A1 (es) 2007-03-22 2008-03-24 Anticuerpos anti-ige apoptoticos
PE2013000851A PE20140771A1 (es) 2007-03-22 2008-03-24 Anticuerpos anti-ige apoptoticos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008000526A PE20090726A1 (es) 2007-03-22 2008-03-24 Anticuerpos anti-ige apoptoticos

Country Status (32)

Country Link
US (6) US8071097B2 (es)
EP (2) EP2644621B1 (es)
JP (3) JP5723594B2 (es)
KR (1) KR101555068B1 (es)
CN (2) CN103554263B (es)
AR (1) AR066198A1 (es)
AU (1) AU2008228778B2 (es)
BR (1) BRPI0808291A2 (es)
CA (1) CA2681341A1 (es)
CL (1) CL2008000839A1 (es)
CO (1) CO6241138A2 (es)
CR (1) CR11035A (es)
CY (1) CY1115257T1 (es)
DK (1) DK2132230T3 (es)
EC (1) ECSP099645A (es)
ES (1) ES2478242T3 (es)
HK (1) HK1194743A1 (es)
HR (1) HRP20140661T1 (es)
IL (1) IL200752A0 (es)
MA (1) MA31312B1 (es)
MX (1) MX2009010092A (es)
NZ (1) NZ580553A (es)
PE (2) PE20090726A1 (es)
PL (1) PL2132230T3 (es)
PT (1) PT2132230E (es)
RS (1) RS53402B (es)
RU (1) RU2500686C2 (es)
SI (1) SI2132230T1 (es)
TW (1) TWI464178B (es)
UA (1) UA102994C2 (es)
WO (1) WO2008116149A2 (es)
ZA (1) ZA201205868B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4063769B2 (ja) * 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
ES2543630T3 (es) * 2003-04-01 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y sus epítopos
US8137670B2 (en) 2005-09-29 2012-03-20 Medimmune, Llc Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
US8071097B2 (en) * 2007-03-22 2011-12-06 Genentech, Inc. Apoptotic anti-IgE antibodies
AU2009231733B2 (en) 2008-03-31 2015-12-24 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
AU2014203008B2 (en) * 2009-02-25 2016-03-31 Academia Sinica Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
JP5848133B2 (ja) 2009-02-25 2016-01-27 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体
JP5925116B2 (ja) 2009-04-29 2016-05-25 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Ｅｒｇモノクローナル抗体
ES2615881T3 (es) 2009-05-07 2017-06-08 Stallergenes Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
EP2384766A1 (en) * 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel antibody to a carbonic anhydrase
US10017762B2 (en) * 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
TWI666447B (zh) 2010-12-16 2019-07-21 建南德克公司 關於ｔｈ２抑制作用之診斷及治療
US10086005B2 (en) 2011-04-12 2018-10-02 University Of Cincinnati Methods for suppressing allergic reactions
US9795618B2 (en) * 2014-02-28 2017-10-24 University Of Cincinnati Methods and compositions for suppressing IgE-mediated anaphylaxis
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
CN104334184B (zh) 2011-10-28 2017-12-29 普罗典娜生物科学有限公司 识别α‑突触核蛋白的人源化抗体
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
AU2013211874B2 (en) 2012-01-27 2017-11-02 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
AU2013215332A1 (en) 2012-01-31 2014-09-04 Genentech, Inc. Anti-Ig-E M1' antibodies and methods using same
CN104603150A (zh) * 2012-04-20 2015-05-06 中央研究院 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
EP3427721A1 (en) 2012-05-18 2019-01-16 Genentech, Inc. High-concentration monoclonal antibody formulations
WO2014041544A1 (en) 2012-09-12 2014-03-20 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9718891B2 (en) 2013-03-13 2017-08-01 Academia Sinica Antibodies specific to a novel epitope on CεMX of human membrane-bound IgE and uses thereof in treating IgE-mediated diseases
MY173295A (en) * 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
WO2014203454A1 (ja) * 2013-06-19 2014-12-24 ソニー株式会社 表示制御装置、表示制御方法、およびプログラム
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015061441A1 (en) 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
EP3092007A4 (en) * 2014-01-10 2017-06-07 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
EP3110848B1 (en) 2014-02-28 2024-02-14 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
CN106573972B (zh) * 2014-06-17 2021-04-06 中央研究院 交联B淋巴细胞的CD23但不致敏肥大细胞的人源化抗-IgE抗体
JP2017536102A (ja) * 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
BR112017011909A2 (pt) 2014-12-05 2018-02-27 Eureka Therapeutics Inc ?antígeno de maturação de célula b alvo de receptores de antígeno quimérico e usos do mesmo?
NZ732568A (en) 2014-12-05 2023-03-31 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
TWI691512B (zh) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
CN107980046B (zh) * 2015-04-13 2021-12-24 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
CN107849119A (zh) 2015-07-07 2018-03-27 阿费里斯股份公司 用于治疗和预防IgE介导的疾病的疫苗
CN108136008A (zh) * 2015-07-15 2018-06-08 华盛顿大学 针对具有末端GlcNAcβ残基的肿瘤相关复合N-聚糖的抗体及其使用方法
JP6068582B2 (ja) * 2015-08-07 2017-01-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体
MA46681A (fr) * 2016-01-28 2019-09-11 Janssen Biotech Inc Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
EP3484517A4 (en) 2016-07-18 2020-04-15 Ramot at Tel-Aviv University Ltd. MODULAR PLATFORM FOR TARGETED THERAPEUTICS
US11384156B2 (en) 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
KR20220151021A (ko) 2016-09-01 2022-11-11 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
CA3041717A1 (en) * 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
KR102579836B1 (ko) 2016-12-22 2023-09-15 제넨테크, 인크. 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제
CN117357638A (zh) 2017-02-17 2024-01-09 弗雷德哈钦森癌症中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
MX2019002289A (es) 2017-04-21 2019-09-26 Ami Pharm Co Ltd Composicion inyectable para reduccion de grasa localizada, sin dolor, edema ni efectos secundarios, y metodo para preparar la misma.
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CN111741768A (zh) 2017-10-31 2020-10-02 合一生技股份有限公司 治疗IgE介导的过敏性疾病
SG11202003866QA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
CA3226165A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2019222055A1 (en) 2018-05-13 2019-11-21 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
KR20210084485A (ko) * 2018-10-01 2021-07-07 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 다중 항체 이소타입의 동시 분리능을 갖는 고 특이성 및 민감도 면역 흡착제 진단 분석
MX2021011141A (es) * 2019-03-21 2022-01-19 Regeneron Pharma Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia.
SG11202113312VA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
CN111411066B (zh) * 2020-03-30 2022-08-23 江南大学 一种双途径复合产神经氨酸枯草芽孢杆菌及构建方法
CN117467016B (zh) * 2023-12-27 2024-03-12 北京索莱宝科技有限公司 人IgA的抗体、抗体组合及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714759A (en) 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
US5254671A (en) 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5252467A (en) 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5342924A (en) * 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5428133A (en) 1987-12-31 1995-06-27 Tanox Biosystems, Inc. Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
US5362643A (en) 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5260416A (en) 1987-12-31 1993-11-09 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgE
US5690934A (en) 1987-12-31 1997-11-25 Tanox Biosystems, Inc. Peptides relating to the extracellular membrane-bound segment of human alpha chain
US5484907A (en) 1989-06-21 1996-01-16 Tanox Biosystems, Inc. Nucleotides coding for the extracellular membrane-bound segment of IgA
US5422258A (en) 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5514776A (en) 1987-12-31 1996-05-07 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface
US5274075A (en) 1987-12-31 1993-12-28 Tanox Biosystems, Inc. Newly identified human epsilon immunoglobulin peptides and related products
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
JP2724625B2 (ja) 1987-12-31 1998-03-09 タノックス・バイオシステムズ・インコーポレーテッド ＩｇＥ産出性Ｂリンパ球上の独特な抗原決定基
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5079344A (en) 1989-06-21 1992-01-07 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgA
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
US5310875A (en) 1989-06-21 1994-05-10 Tanox Biosystems, Inc. Peptides corresponding to membrane-bound IgA
AU645783B2 (en) * 1990-01-23 1994-01-27 Tanox Biosystems, Inc. Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
CN1167491A (zh) 1994-10-25 1997-12-10 美国联合生物医学公司 用于治疗变态反应的合成IgE膜锚肽免疫原
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
EP2000481B1 (en) 2003-02-01 2016-03-30 Tanox, Inc. High affinity anti-human IgE antibodies
CN1926149A (zh) * 2004-02-02 2007-03-07 泰勒公司 新的IgE表位的鉴别
CA2555820C (en) 2004-02-19 2016-01-19 Genentech, Inc. Cdr-repaired antibodies
US8137670B2 (en) * 2005-09-29 2012-03-20 Medimmune, Llc Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
US8071097B2 (en) 2007-03-22 2011-12-06 Genentech, Inc. Apoptotic anti-IgE antibodies

Also Published As

Publication number Publication date
JP2010521989A (ja) 2010-07-01
KR20100015754A (ko) 2010-02-12
ECSP099645A (es) 2009-10-30
TW200848432A (en) 2008-12-16
CR11035A (es) 2009-12-03
CL2008000839A1 (es) 2008-09-26
JP2015017103A (ja) 2015-01-29
CA2681341A1 (en) 2008-09-25
WO2008116149A3 (en) 2008-11-06
US8071097B2 (en) 2011-12-06
CN103554263A (zh) 2014-02-05
US20120144512A1 (en) 2012-06-07
EP2644621B1 (en) 2017-12-13
US20120149881A1 (en) 2012-06-14
CO6241138A2 (es) 2011-01-20
IL200752A0 (en) 2010-05-17
US8586040B2 (en) 2013-11-19
RS53402B (en) 2014-10-31
MX2009010092A (es) 2010-02-09
US20120177635A1 (en) 2012-07-12
SI2132230T1 (sl) 2014-07-31
ZA201205868B (en) 2014-04-30
RU2009138932A (ru) 2011-04-27
CN101679528B (zh) 2013-11-06
CN101679528A (zh) 2010-03-24
PE20090726A1 (es) 2009-06-23
UA102994C2 (ru) 2013-09-10
DK2132230T3 (da) 2014-06-30
MA31312B1 (fr) 2010-04-01
JP2017048190A (ja) 2017-03-09
AU2008228778B2 (en) 2014-05-22
EP2644621A1 (en) 2013-10-02
US20120178127A1 (en) 2012-07-12
NZ580553A (en) 2012-05-25
CN103554263B (zh) 2016-09-28
CY1115257T1 (el) 2017-01-04
JP5723594B2 (ja) 2015-05-27
US8618274B2 (en) 2013-12-31
EP2132230A2 (en) 2009-12-16
PL2132230T3 (pl) 2014-09-30
AU2008228778A1 (en) 2008-09-25
BRPI0808291A2 (pt) 2018-12-11
US20140115729A1 (en) 2014-04-24
KR101555068B1 (ko) 2015-10-06
HK1194743A1 (zh) 2014-10-24
EP2132230B1 (en) 2014-04-16
WO2008116149A2 (en) 2008-09-25
ES2478242T3 (es) 2014-07-21
PT2132230E (pt) 2014-07-17
US8632775B2 (en) 2014-01-21
HRP20140661T1 (hr) 2014-10-10
AR066198A1 (es) 2009-08-05
RU2500686C2 (ru) 2013-12-10
TWI464178B (zh) 2014-12-11
US20090010924A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
PE20140771A1 (es) Anticuerpos anti-ige apoptoticos
PE20120878A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
PE20120877A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
PE20150614A1 (es) Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20150211A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso
PE20140995A1 (es) Agonistas de fgfr1 y sus metodos de uso
AR091701A1 (es) Anticuerpos anti-cd22 e inmunoconjugados
PE20201186A1 (es) Anticuerpos antitau y metodos de uso
NZ597251A (en) Antibodies and immunoconjugates and uses therefor
HRP20201493T1 (hr) Anti-alfa-sinukleinska protutijela i postupci uporabe
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
PE20120553A1 (es) Anticuerpos anti-fgfr3
JP2020500538A5 (es)
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
PE20160712A1 (es) Anticuerpos e inmunoconjugados anti-cd33
JP2015533795A5 (es)
PE20170935A1 (es) Anticuerpos anti-her2 e inmunoconjugados
WO2013003680A8 (en) Anti-c-met antibody formulations
PE20141114A1 (es) Anticuerpos anti-mesotelina e inmunoconjugados
PE20191758A1 (es) Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
RU2014136332A (ru) Композиции и способы применения ингибиторов csf1r
PE20161376A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso
JP2015510510A5 (es)

Legal Events

Date Code Title Description
FD Application declared void or lapsed